NT157 is a selective IRS-1/2 inhibitor with potential to suppress IGF-1R and STAT3 signaling pathways in both cancer cells and stromal cells within the tumor microenvironment, thereby reducing cancer cell survival. It inhibits IGF1R activation, IRS protein expression, and IGF-1-induced AKT activation in a dose-dependent manner, while enhancing ERK activation. These effects are associated with reduced proliferation and increased apoptosis in LNCaP cells, and G2-M cell cycle arrest in PC3 cells. NT157 targets IRS1/2 for serine phosphorylation and degradation via negative feedback regulation of IGF1R signaling, thus inhibiting IGF1R-mediated survival signals. It exhibits minimal or no cytotoxic effects on normal melanocytes and fibroblasts. In vivo, NT157 suppresses androgen-responsive growth of LNCaP xenograft tumors and delays the development of castration-resistant prostate cancer (CRPC). It also inhibits the growth of PC3 xenograft tumors when administered alone or in combination with docetaxel, and effectively suppresses melanoma tumor growth and metastasis.